- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dendreon Sees Light at the End of the Provenge Tunnel
The Canadian company Valeant Pharmaceuticals International Inc has reached an agreement to buy the prostate cancer immunotherapy from Dendreon Corp.
Valeant Pharmaceuticals International Inc. said late Thursday it has reached a tentative deal to buy the prostate- cancer drug Provenge and other assets from Dendreon Corp. for $296 million in cash.
Quebec-based Valeant said it has entered into a so-called stalking-horse agreement, which means it is the preferred bidder and the company would receive an unspecified breakup fee and reimbursed expenses if its bid doesn't win the auction for Dendreon's assets. A bankruptcy court also must approve Valeant's stalking-horse bid and the sale, Valeant said.
Read complete news on Nasdaq: http://bit.ly/18CptIA
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer
April 9th 2025New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with metastatic pancreatic cancer are less likely to receive recommended treatments and achieve longer survival.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
